Cardiac Malformations Are Associated with Altered Expression of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase Genes in Embryos of Diabetic Mice
Restricted accessOtherFirst published online November, 2008
Cardiac Malformations Are Associated with Altered Expression of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase Genes in Embryos of Diabetic Mice
The aim of this study was to investigate the role of nitric oxide (NO), and the expression of endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) genes in developing hearts at embryonic day 13.5 of embryos from diabetic mice. The protein and mRNA expression levels of eNOS and VEGF were significantly altered in the developing hearts of embryos from diabetic mice. The NO level was significantly decreased, whereas the VEGF concentration was significantly increased in the developing hearts of the embryos from diabetic mice. In vitro study showed a significant reduction in eNOS expression and cell proliferation in cardiac myoblast cells exposed to high glucose concentrations. Further, high glucose induced apoptosis in myoblast cells. Ultrastructural changes characteristics of apoptosis, including cell blebbing, aggregation of ribosomes and vacuoles in the cytoplasm were also evident in myoblast cells exposed to high glucose. It is suggested that hyperglycemia alters the expression of eNOS and VEGF genes that are involved in the regulation of cell growth and vasculogenesis, thereby contributing to the cardiac malformations seen in embryos from diabetic mice.
Get full access to this article
View all access options for this article.
References
1.
Hawthorne G, Robson S, Ryall EA, Sen D, Roberts SH, Ward Platt MP. Prospective population based survey of outcome of pregnancy in diabetic women: results of the Northern Diabetic Pregnancy Audit, 1994. BMJ315:279–281, 1997.
2.
Kuhl C, Coustan D, Kitzmiller J, Philipps A, Binder C, Schneider H. Report on the 28th annual meeting of the Diabetic Pregnancy Study Group. Diabetologia41:suppl 8–14, 1998.
3.
Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia43:79–82, 2000.
4.
Aberg A, Westbom L, Kallen B. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev61:85–95, 2001.
5.
Lazarow A, Kim JN, Wells LJ. Birth weight and fetal mortality in pregnant subdiabetic rats. Diabetes9:114–117, 1960.
6.
Wentzel P, Wentzel CR, Gareskog MB, Eriksson UJ. Induction of embryonic dysmorphogenesis by high glucose concentration, disturbed inositol metabolism, and inhibited protein kinase C activity. Teratology63:193–201, 2001.
7.
Pedersen LM, Tygstrup I, Pedersen J. Congenital malformations in newborn infants of diabetic women. Correlation with maternal diabetic vascular complications. Lancet1:1124–1126, 1964.
8.
Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM94:435–444, 2001.
9.
Cockroft DL, Coppola PT. Teratogenic effects of excess glucose on head-fold rat embryos in culture. Teratology16:141–146, 1977.
10.
Ellington SK. In-vivo and in-vitro studies on the effects of maternal fasting during embryonic organogenesis in the rat. J Reprod Fertil60: 383–388, 1980.
11.
Miller E, Hare JW, Cloherty JP, Dunn PJ, Gleason RE, Soeldner JS, Kitzmiller JL. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med304:1331–1334, 1981.
12.
Mills JL, Baker L, Goldman AS. Malformations in infants of diabetic mothers occur before the seventh gestational week. Implications for treatment. Diabetes28:292–293, 1979.
13.
Baker L, Piddington R, Goldman A, Egler J, Moehring J. Myo-inositol and prostaglandins reverse the glucose inhibition of neural tube fusion in cultured mouse embryos. Diabetologia33:593–596, 1990.
14.
Eriksson UJ, Borg LA. Protection by free oxygen radical scavenging enzymes against glucose-induced embryonic malformations in vitro. Diabetologia34:325–331, 1991.
15.
Eriksson UJ, Borg LA. Diabetes and embryonic malformations. Role of substrate-induced free-oxygen radical production for dysmorphogenesis in cultured rat embryos. Diabetes42:411–419, 1993.
16.
Eriksson UJ, Cederberg J, Wentzel P. Congenital malformations in offspring of diabetic mothers—animal and human studies. Rev Endocr Metab Disord4:79–93, 2003.
17.
Kumar SD, Dheen ST, Tay SS. Maternal diabetes induces congenital heart defects in mice by altering the expression of genes involved in cardiovascular development. Cardiovasc Diabetol6:34, 2007.
18.
Klagsbrun M, D’Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev7:259–270, 1996.
19.
Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension23:1121–1131, 1994.
20.
Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A90:347–351, 1993.
21.
Bloch W, Fleischmann BK, Lorke DE, Andressen C, Hops B, Hescheler J, Addicks K. Nitric oxide synthase expression and role during cardiomyogenesis. Cardiovasc Res43:675–684, 1999.
22.
Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, Yee SP. Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation106:873–879, 2002.
23.
Miquerol L, Langille BL, Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development127:3941–3946, 2000.
24.
Sissman NJ. Developmental landmarks in cardiac morphogenesis: comparative chronology. Am J Cardiol25:141–148, 1970.
25.
Kaufman MH. The Atlas of Mouse Development. New York: Academic Press, 1992.
26.
Srinivasan S, Baldwin HS, Aristizabal O, Kwee L, Labow M, Artman M, Turnbull DH. Noninvasive, in utero imaging of mouse embryonic heart development with 40-MHz echocardiography. Circulation98: 912–918, 1998.
27.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem72:248–254, 1976.
28.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods25:402–408, 2001.
29.
Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics85:1–9, 1990.
30.
Dinleyici EC, Tekin N, Dinleyici M, Kilic Z, Adapinar B, Aksit MA. Severe fatal course of axial mesodermal dysplasia spectrum associated with complex cardiac defect in an infant of a mother with insulin dependent diabetes. Am J Med Genet A143:2156–2159, 2007.
31.
Schafer K, Neuhaus P, Kruse J, Braun T. The homeobox gene Lbx1 specifies a subpopulation of cardiac neural crest necessary for normal heart development. Circ Res92:73–80, 2003.
32.
Ferencz C, Rubin JD, McCarter RJ, Clark EB. Maternal diabetes and cardiovascular malformations: predominance of double outlet right ventricle and truncus arteriosus. Teratology41:319–326, 1990.
33.
Molin DG, Roest PA, Nordstrand H, Wisse LJ, Poelmann RE, Eriksson UJ, Gittenberger-De Groot AC. Disturbed morphogenesis of cardiac outflow tract and increased rate of aortic arch anomalies in the offspring of diabetic rats. Birth Defects Res A Clin Mol Teratol70:927–938, 2004.
34.
Smoak IW. Hyperglycemia-induced TGFbeta and fibronectin expression in embryonic mouse heart. Dev Dyn231:179–189, 2004.
35.
Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol273:H2224–H2231, 1997.
36.
Dor Y, Camenisch TD, Itin A, Fishman GI, McDonald JA, Carmeliet P, Keshet E. A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development128: 1531–1538, 2001.
37.
Cooper RG, Taylor CM, Choo JJ, Weiss JB. Elevated endothelial-cell-stimulating angiogenic factor activity in rodent glycolytic skeletal muscles. Clin Sci (Lond)81:267–270, 1991.
38.
Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation104:2344–2350, 2001.
39.
Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes46:1497–1503, 1997.
40.
Roguin A, Nitecki S, Rubinstein I, Nevo E, Avivi A, Levy NS, Abassi ZA, Sabo E, Lache O, Frank M, Hoffman A, Levy AP. Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model. Cardiovasc Diabetol2:18, 2003.
41.
Enciso JM, Gratzinger D, Camenisch TD, Canosa S, Pinter E, Madri JA. Elevated glucose inhibits VEGF-A-mediated endocardial cushion formation: modulation by PECAM-1 and MMP-2. J Cell Biol160:605–615, 2003.
42.
Hallaq H, Pinter E, Enciso J, McGrath J, Zeiss C, Brueckner M, Madri J, Jacobs HC, Wilson CM, Vasavada H, Jiang X, Bogue CW. A null mutation of Hhex results in abnormal cardiac development, defective vasculogenesis and elevated Vegfa levels. Development131:5197–5209, 2004.
43.
Watanabe M, Choudhry A, Berlan M, Singal A, Siwik E, Mohr S, Fisher SA. Developmental remodeling and shortening of the cardiac outflow tract involves myocyte programmed cell death. Development125:3809–3820, 1998.
44.
Abdelwahid E, Pelliniemi LJ, Niinikoski H, Simell O, Tuominen J, Rahkonen O, Jokinen E. Apoptosis in the pattern formation of the ventricular wall during mouse heart organogenesis. Anat Rec256:208–217, 1999.
45.
Brune B. The intimate relation between nitric oxide and superoxide in apoptosis and cell survival. Antioxid Redox Signal7:497–507, 2005.
46.
Ornoy A. Embryonic oxidative stress as a mechanism of teratogenesis with special emphasis on diabetic embryopathy. Reprod Toxicol24:31–41, 2007.
47.
Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes51:1938–1948, 2002.
48.
Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, Limana F, Nadal-Ginard B, Leri A, Anversa P. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes50:1414–1424, 2001.
